Amgen Inc. $AMGN Shares Sold by Martingale Asset Management L P

Key Points

• Martingale Asset Management trimmed its Amgen stake by 9.2% in Q3, selling 6,168 shares and leaving it with 60,602 shares valued at about $17.10 million.
• Amgen reported a quarterly earnings beat (EPS $5.29 vs. $4.76 est.) and revenue of $9.87B, raised FY2026 EPS guidance to a 21.600–23.000 range, with analysts forecasting roughly 20.62 EPS for the year.
• The company pays a quarterly dividend of $2.52 ($10.08 annual, ~2.7% yield), and the stock trades near $367.79 with a market cap of about $198.3B and a P/E of 25.85.

Martingale Asset Management L P cut its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,602 shares of the medical research company's stock after selling 6,168 shares during the quarter. Martingale Asset Management L P's holdings in Amgen were worth $17,102,000 as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Evelyn Partners Investment Management LLP acquired a new position in shares of Amgen in the second quarter worth $32,000. Howard Hughes Medical Institute purchased a new stake in shares of Amgen in the 2nd quarter worth approximately $32,000. Cloud Capital Management LLC acquired a new stake in Amgen in the third quarter valued at $34,000. AXS Investments LLC bought a new stake in shares of Amgen in the 3rd quarter valued at approximately $42,000. Finally, Winnow Wealth LLC bought a new stake in Amgen in the third quarter valued at about $47,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 2.6%

Shares of Amgen stock opened at $367.79 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The business has a fifty day simple moving average of $356.96 and a two-hundred day simple moving average of $324.63. The company has a market capitalization of $198.26 billion, a price-to-earnings ratio of 25.85, a P/E/G ratio of 3.75 and a beta of 0.45.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen's quarterly revenue was up 8.6% compared to the same quarter last year. During the same period last year, the company earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts forecast that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. The Goldman Sachs Group raised their target price on shares of Amgen from $403.00 to $415.00 and gave the company a "buy" rating in a report on Wednesday, February 4th. Piper Sandler boosted their target price on Amgen from $381.00 to $432.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 18th. Scotiabank assumed coverage on Amgen in a research report on Thursday, November 13th. They issued a "sector outperform" rating and a $385.00 target price for the company. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $285.00 to $295.00 and gave the company a "hold" rating in a research report on Thursday, February 5th. Finally, Oppenheimer set a $400.00 price objective on Amgen and gave the company an "outperform" rating in a report on Thursday, January 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, Amgen has an average rating of "Hold" and an average target price of $354.00.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: MariTide and osteoporosis drug sales cited as a key driver of recent investor enthusiasm; analysts/coverage note product momentum that helped push earlier gains. Amgen: MariTide And Osteoporosis Sales Fuel The Rally
• Positive Sentiment: Operational/production support: Rapid Micro Biosystems reported that Amgen expanded a global Growth Direct system rollout (multi‑system order), signaling investments in manufacturing capacity and process efficiency. Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
• Positive Sentiment: Institutional buying/positioning: Amgen is highlighted as a holding in a large income fund, reflecting demand from dividend/income managers seeking defensive, high‑yield large caps. Starbucks, Amgen, and CVS Help This Income Fund Shine
• Positive Sentiment: Macro/sector support: Prominent market commentators have endorsed large‑cap biotech as resilient growth plays, which supports longer‑term investor interest. Josh Brown: Biotech growth stocks immune to disruption risk
• Neutral Sentiment: Company presentation: A recent Leerink Global Healthcare conference transcript provides updated management commentary — useful for gauging near‑term guidance and pipeline cadence but not an immediate catalyst by itself. Amgen Inc. (AMGN) Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Valuation discussion: Coverage pieces assessing whether AMGN is mispriced highlight mixed returns vs. peers — useful context for investors but not a direct price mover. Assessing Whether Amgen (AMGN) Shares Look Mispriced After Recent Mixed Returns
• Neutral Sentiment: Short‑interest data appears to contain errors (reports show zero shares/NaN changes and a 0.0 days-to-cover figure); there’s no clear evidence of meaningful short pressure at present.
• Negative Sentiment: Analyst stance: Jefferies initiated coverage with a Hold recommendation, which can cap momentum relative to a Buy/Outperform narrative and may contribute to near‑term selling pressure. Jefferies initiates coverage of Amgen (AMGN) with hold recommendation

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.